The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASDAQ. On the latest BioCentury This Week, BioCentury’s analysts discuss the $3.25 billion takeout of in vivo CAR T company Kelonia Therapeutics by Eli Lilly, the market debut by obesity play Kailera Therapeutics and an upsized follow-on by Revolution Medicines.
The analysts also discuss how autoimmune T cell engagers are diverging from their oncology roots and the potential implications of President Donald Trump’s executive order on psychedelic therapies. BioCentury’s analysts also take time to remember Sofinnova Partners’ Denis Lucquin, father of French biotech.
This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.

View full story: https://www.biocentury.com/article/659183

#BiotechMA #BiotechIPO #CART #TCellEngagers #PsychedelicMedicine

00:01 - Sponsor Message: IQVIA Biotech
04:20 - Lilly's Kelonia Buy
10:31 - T Cell Engagers
23:07 - Psychedelics Executive Order
35:14 - CBER Director Search
37:37 - Public Markets Roundup
42:14 - Remembering Denis Lucquin

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers

BioCentury This Week

Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers